tiprankstipranks
Blurbs

H.C. Wainwright Reaffirms Their Buy Rating on Spero Therapeutics (SPRO)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Spero Therapeutics (SPROResearch Report) today and set a price target of $6.00. The company’s shares closed last Friday at $1.97.

Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, Aeterna Zentaris, and Enlivex Therapeutics. According to TipRanks, Selvaraju has an average return of -36.3% and a 12.41% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spero Therapeutics with a $6.00 average price target, representing a 204.57% upside. In a report released on September 23, Evercore ISI also upgraded the stock to a Buy with a $8.00 price target.

See the top stocks recommended by analysts >>

SPRO market cap is currently $69.08M and has a P/E ratio of -0.57.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Read More on SPRO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles